Show simple item record

dc.contributor.authorMarott, Jacob Louis
dc.contributor.authorIngebrigtsen, Truls Sylvan
dc.contributor.authorÇolak, Yunus
dc.contributor.authorKankaanranta, Hannu
dc.contributor.authorBakke, Per S.
dc.contributor.authorVestbo, Jørgen
dc.contributor.authorNordestgaard, Børge Grønne
dc.contributor.authorLange, Peter
dc.date.accessioned2024-08-05T09:26:53Z
dc.date.available2024-08-05T09:26:53Z
dc.date.created2023-11-28T14:18:13Z
dc.date.issued2023
dc.identifier.issn2666-7762
dc.identifier.urihttps://hdl.handle.net/11250/3144385
dc.description.abstractBackground Whether the metabolic syndrome plays a role for the prognosis of individuals with lung function impairment (preserved ratio impaired spirometry (PRISm) or airflow limitation) is unclear. We hypothesised that the metabolic syndrome in individuals with lung function impairment is associated with increased cardiopulmonary morbidity and mortality. Methods The Copenhagen General Population Study was initiated in 2003 based on a random sample of white men and women aged 20–100 years drawn from the Danish general population. The risk of ischemic heart disease/heart failure, respiratory disease, and all-cause mortality was analysed with Cox models adjusted for age, sex, current smoking, and asthma during 15 years of follow-up. Findings Among 106,845 adults, 86,159 had normal lung function, 6126 had PRISm, and 14,560 had airflow limitation. We observed 10,448 hospital admissions for ischemic heart disease/heart failure, 21,140 for respiratory disease, and 11,125 deaths. Individuals with versus individuals without the metabolic syndrome generally had higher 5-year absolute risk of all outcomes, including within those with normal lung function, mild-moderate-severe PRISm, and very mild-mild-moderate-severe airflow limitation alike. Compared to individuals without the metabolic syndrome and with normal lung function, those with both the metabolic syndrome and severe PRISm had hazard ratios of 3.74 (95% CI: 2.53–5.55; p < 0.0001) for ischemic heart disease/heart failure, 5.02 (3.85–6.55; p < 0.0001) for respiratory disease, and 5.32 (3.76–7.54; p < 0.0001) for all-cause mortality. Corresponding hazard ratios in those with both the metabolic syndrome and severe airflow limitation were 2.89 (2.34–3.58; p < 0.0001) for ischemic heart disease/heart failure, 5.98 (5.28–6.78; p < 0.0001) for respiratory disease, and 4.16 (3.50–4.95; p < 0.0001) for all-cause mortality, respectively. The metabolic syndrome explained 13% and 27% of the influence of PRISm or airflow limitation on ischemic heart disease/heart failure and all-cause mortality. Interpretation The metabolic syndrome conferred increased risk of cardiopulmonary morbidity and mortality at all levels of lung function impairment.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleImpact of the metabolic syndrome on cardiopulmonary morbidity and mortality in individuals with lung function impairment: a prospective cohort study of the Danish general populationen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.articlenumber100759en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.lanepe.2023.100759
dc.identifier.cristin2204068
dc.source.journalThe Lancet Regional Health - Europeen_US
dc.identifier.citationThe Lancet Regional Health - Europe. 2023, 35, 100759.en_US
dc.source.volume35en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal